Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351366 | 0.86 | GPR119 (0.54) | SMN1; SMN2 | |
| SCHEMBL16697161 | 0.84 | MET (0.44) | F2METNQO2PDE4D | |
| SCHEMBL2223511 | 0.84 | MET (0.52) | HRH3AVPR1BMETNQO2CHRM3 | |
| SCHEMBL2351356 | 0.82 | CYP4F2 (0.49) | HRH3F2AVPR1BMETNQO2 | |
| SCHEMBL2221443 | 0.80 | CYP4F2 (0.44) | — | |
| SCHEMBL4259566 | 0.77 | CHRNA3 (0.53) | — | |
| SCHEMBL20893497 | 0.76 | GPR119 (0.43) | METNQO2 | |
| SCHEMBL20893496 | 0.75 | GPR119 (0.38) | METNQO2 | |
| SCHEMBL23344107 | 0.75 | MET (0.54) | HRH3METNQO2 | |
| SCHEMBL15155542 | 0.75 | DGAT1 (0.50) | HRH3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | HRH3 2576/4885F2 4863/4885CNR1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.